These discrepancies emphasize the need for further investigations to clarify the molecular mechanisms of ATG4D in NPC, and assess how targeting this gene might influence DMFS and overall treatment outcomes. This evidence concerns the gene ATG4D and nasopharyngeal carcinoma.